[PR Newswire] – NORTH CHICAGO, Ill., June 7, 2016 /PRNewswire/ — AbbVie, a global biopharmaceutical company, today announced the launch of What’s Your Sore Spot?, a disease education campaign to connect people impacted by hidradenitis suppurativa (HS), a painful, chronic, inflammatory skin disease,2 with educational resources designed to help them obtain an accurate diagnosis. The campaign, which is launching during HS Awareness Week (June 6 – 12), features WhatsYourSoreSpot.com, a gateway to more than two dozen country-specific websites with useful tools and resources about HS, including a symptom checker and discussion guide. Read more on this. AbbVie Inc. (ABBV) , valued at $102.39B, opened at $62.59. During today’s session, ABBV traded between $62.30 to $63.59 with its 52-week range being $45.45 to $71.60. ABBV shares are currently priced at 13.20x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.21x forward p/e ratio. The company pays shareholders $2.28 per share annually in dividends, yielding 3.51%. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $1.20 per share, which would be $0.12 better than the year-ago quarter and a $0.03 sequential decrease. In looking at the bigger picture, the full-year EPS estimate of $4.76 would be a $0.47 better when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $6.20 Billion. If realized, that would be a 13.14% increase over the year-ago quarter. More recently, Societe Generale Initiated ABBV at Sell (Apr 6, 2016). Previously, Deutsche Bank Initiated ABBV at to Hold. The average price target for ABBV shares is $70.67, which is 12.91% above where the stock opened this morning. See more in (NYSE:ABBV) Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie’s Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016) Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirr Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie’s Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia